Triple-negative breast cancer trials in China

In China 133 Also abroad 423

133 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
Where
Shanghai
Age
18 years and over
People
120
Run by
Fudan University
See details and how to joinNCT05749588
Phase 3Taking people
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
Where
Guangzhou
Age
18 years to 75 years
People
364
Run by
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
See details and how to joinNCT07533123
Phase 2Taking people
JS207 Combination Therapy in Triple-negative Breast Cancer
Where
Baoding, Beijing, Changchun, Dalian, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Qingdao, Shenyang, Ürümqi, Wuhan, Xian, Yinchuan, Zhangzhou
Age
18 years to 75 years
People
80
Run by
Shanghai Junshi Bioscience Co., Ltd.
See details and how to joinNCT07045311
Phase 1/2Taking people
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Where
Shenzhen
Age
18 years to 75 years
People
72
Run by
Beijing Biotech
See details and how to joinNCT07523529
No phaseNot yet taking people in China
Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC
Where
Nanjing
Age
18 years and over
People
201
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07523789
Phase 1/2Taking people
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
Where
Shenzhen
Age
18 years to 75 years
People
60
Run by
Beijing Biotech
See details and how to joinNCT07510802
Phase 2Taking people
Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
Where
Dongguan, Guangzhou, Lanzhou, Zhanjiang, Zigong
Age
18 years and over
People
192
Run by
Sun Yat-sen University
See details and how to joinNCT06768931
Phase 3Taking people
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
Where
Shanghai
Age
18 years to 70 years
People
134
Run by
Fudan University
See details and how to joinNCT05806060
Phase 2Not yet taking people in China
Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.
Where
Harbin
Age
18 years and over
People
180
Run by
Shanghai Henlius Biotech
See details and how to joinNCT07487519
Phase 1/2Taking people
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
Where
Shenzhen
Age
18 years to 75 years
People
60
Run by
Beijing Biotech
See details and how to joinNCT07486089
Phase 3Taking people
AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
Where
Beijing
Age
18 years to 75 years
People
416
Run by
Akeso
See details and how to joinNCT06767527
Phase 2Not yet taking people in China
Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer
Where
Xi'an
Age
18 years to 70 years
People
84
Run by
Xijing Hospital
See details and how to joinNCT07466303
Phase 2Taking people
Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer
Where
Hangzhou
Age
18 years to 75 years
People
18
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07457359
Phase 2Taking people
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer
Where
Nantong
Age
18 years and over
People
30
Run by
Affiliated Hospital of Nantong University
See details and how to joinNCT07342283
Phase 2Not yet taking people in China
Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)
Where
Beijing
Age
18 years and over
People
78
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07413601
Phase 1/2Taking people
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
Where
Changchun, Guangzhou, Harbin, Nanjing, Shenyang, Zhengzhou
Age
18 years and over
People
220
Run by
Nanjing Leads Biolabs Co.,Ltd
See details and how to joinNCT07281976
Phase 2Taking people
Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer
Where
Guangzhou
Age
18 years to 70 years
People
416
Run by
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07401537
Phase 2Enrolling by invitation
A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
Where
Anyang, Changsha, Chengdu, Fujian, Guangdong, Guangzhou, Hangzhou, Harbin, Hefei, Jilin City, Jining, Linyi, Nanjing, Shandong, Shanghai, Shanxi, Shengyang, Suzhou, Tianjing, Wuhan, Xiamen, Xi'an, Xuzhou
Age
18 years to 75 years
People
60
Run by
Huabo Biopharm Co., Ltd.
See details and how to joinNCT07376629
Phase 2Taking people
Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer
Where
Shanghai
Age
18 years to 65 years
People
40
Run by
Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT07371208
Phase 2Enrolling by invitation
Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC
Where
Beijing
Age
18 years and over
People
60
Run by
YING FAN
See details and how to joinNCT07359404
Phase 3Taking people
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
Where
Beijing, Chengdu, Chongqing, Fuzhou, Guangdong, Guangzhou, Nantong, Ningbo, Shanghai, Shenyang, Xi’an, Yangzhou
Age
18 years to 70 years
People
764
Run by
Fudan University
See details and how to joinNCT05909332
Phase 2Taking people
Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)
Where
Hefei, Shanghai
Age
18 years to 75 years
People
37
Run by
First Affiliated Hospital of Zhejiang University
See details and how to joinNCT07351487
Phase 2Taking people
Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
Where
Hangzhou, Harbin, Hefei, Jinhua, Nanchang, Nantong, Shanghai, Shanxi, Xi'an, Xinjiang, Zhengzhou
Age
18 years to 70 years
People
35
Run by
First Affiliated Hospital of Zhejiang University
See details and how to joinNCT06682195
Early phase 1Taking people
A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer.
Where
Jinan
Age
18 years and over
People
15
Run by
Xiaorong Sun
See details and how to joinNCT07340424
Phase 1/2Taking people
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Where
Beijing, Changchun, Jinan
Age
18 years and over
People
102 worldwide
Run by
Jacobio Pharmaceuticals Co., Ltd.
See details and how to joinNCT05490472